BridgeBio Pharma, Inc.（BBIO）財務資料BBIOBridgeBio Pharma, Inc.

Evaluating the bottom line, BridgeBio Pharma, Inc. maintains a gross margin of 93.83%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -43.94%, while the net margin is -63.97%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively BBIO converts its operational activities into shareholder value.

In the context of the broader market, BBIO competes directly with industry leaders such as HALO and SMMT. With a market capitalization of $12.86B, it holds a significant position in the sector. When comparing efficiency, BBIO's gross margin of 93.83% stands against HALO's 77.40% and SMMT's N/A. Such benchmarking helps identify whether BridgeBio Pharma, Inc. is trading at a premium or discount relative to its financial performance.

BridgeBio has demonstrated strong revenue growth, with Q2 2026 revenue at $243,676,000, up from $194,515,000 in Q1 2026. The gross margin remains high at 93.83%, reflecting effective cost management despite ongoing net losses.